{"id":"W4401226031","doi":"10.1177/13524585241267211","title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; St. Michael's Hospital; Cegep de Saint Jerome; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Sanofi Genzyme; EMD Serono; Grifols; Monash University; Alexion Pharmaceuticals; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Atara Biotherapeutics; Medical Research Council; Biogen; Sanofi","keywords":"Medicine; Ocrelizumab; Cladribine; Multiple sclerosis; Natalizumab; Fingolimod; Alemtuzumab; Relapsing remitting; Expanded Disability Status Scale; Internal medicine; Gastroenterology; Oncology; Rituximab; Immunology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003278932,0.0006941097,0.001617578,0.001649854,0.0004872698,0.000351092,0.0004390294,0.0002914339,0.0001070895],"category_scores_gemma":[0.005403033,0.0006158865,0.0004600495,0.001748906,0.0004177516,0.0005504559,0.0006088776,0.001609212,0.00004734884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001079873,"about_ca_system_score_gemma":0.0003462115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008600767,"about_ca_topic_score_gemma":0.0002950399,"domain_scores_codex":[0.9938129,0.0007133802,0.001613875,0.001120437,0.00143076,0.001308703],"domain_scores_gemma":[0.9942026,0.003406071,0.0002727024,0.0006496219,0.0006216096,0.0008474173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.004418231,0.0006644461,0.2739784,0.002830628,0.0006713638,0.0001605918,0.002928037,0.001476408,0.6679527,0.00003704928,0.001563003,0.04331915],"study_design_scores_gemma":[0.01267399,0.0007314181,0.8964492,0.02534245,0.0001316127,0.0002948166,0.0007756099,0.02990181,0.0325013,0.00003894848,0.0005511283,0.0006077157],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884008,0.006631953,0.001277843,0.0007595866,0.000693151,0.001645501,0.0001379586,0.000183279,0.0002699279],"genre_scores_gemma":[0.9908305,0.003016945,0.005361853,0.00008345506,0.0003131757,0.0001471964,0.00003448586,0.0001549136,0.00005748637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6354514,"threshold_uncertainty_score":0.9996293,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09020544279069158,"score_gpt":0.3128205917848402,"score_spread":0.2226151489941486,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}